))
219. CDK 4/6 Inhibitors: What To Do When They Stop Working
Manage episode 397421304 series 3438387
Content provided by SurvivingBreastCancer.org. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by SurvivingBreastCancer.org or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Welcome back to another episode of Breast Cancer Conversations, where we continue to share valuable insights from the San Antonio Breast Cancer Symposium. As a breast cancer survivor and the founder of survivingbreastcancer.org, I'm thrilled to bring you key takeaways from one of the world's largest breast cancer conferences.
In this episode, we focus on what to do when CDK4-6 inhibitors, such as Ibrance, Kisqali, and Verzenio, stop working. Our guest, Amy Bremer, highlights the importance of getting a biopsy to check for mutations, which can be done through a liquid biopsy or a tissue biopsy. This step is crucial for determining the next course of action.
We delve into the various treatment options available based on specific mutations. For instance, if your cancer has a PIK3CA mutation, a combination of PIQRAY and Faslodex might be recommended. Other drugs like Trucap, Orserdo, and LSS strontosome are also discussed as potential options for different mutations.
For those without mutations, there are still choices available, such as Affinitor plus Faslodex, or considering a switch to a different CDK4-6 inhibitor. We also discuss the possibility of continuing treatment beyond progression or, in cases of aggressive progression, looking into chemotherapy or antibody drug conjugates (ADCs).
Stay tuned for our next episode, "on SERDs, SERMs, CERANs, and PROTACs" and remember to subscribe to Breast Cancer Conversations. Please note that our podcast shares personal experiences and is not a substitute for professional medical advice. If you have specific topics in mind or want to be a guest, feel free to reach out to me.
Thank you for listening, and let's continue to empower each other through community, education, and resources.
00:02:44 - Topic: CDK4-6 Inhibitor Efficacy
00:03:31 - Options After Endocrine Therapy and CDK4-6 Inhibitors
00:04:35 - Treatment Options Based on Specific Mutations
00:05:40 - Options Without Identified Mutations
00:06:43 - Inherited Mutations and Treatment Choices
00:07:09 - Expert Opinions on Treatment Complexity
00:08:44 - Importance of Clinical Trials
+++++++++++++++++++++
Attend a free virtual SurvivingBreastCancer.org event:
https://www.survivingbreastcancer.org/events
Follow us on Instagram
Laura and Will: https://www.instagram.com/laura_and_will/
SurvivingBreastCancer.org: https://www.survivingbreastcancer.org/
Breast Cancer Conversations: https://www.instagram.com/breastcancerconversations/
About SurvivingBreastCancer.org: SurvivingBreastCancer.org, Inc. (SBC) is a federally recognized 501(c)(3) non-profit virtual platform headquartered in Boston with a national and global reach. Through education, community, and resources, SurvivingBreastCancer.org supports women and men going through breast cancer. We provide a sanctuary of strength, compassion, and empowerment, where those diagnosed with cancer unite to share their stories, learn invaluable coping strategies to manage wellness and mental health, and find solace in the unbreakable bond that fuels hope, resilience, and the courage to conquer adversity.
237 episodes
Share
